Nabriva Therapeutics of King of Prussia gets OK from FDA for pneumonia drug
Nabriva Therapeutics’ drug application for its antibiotic Xenleta recently got the approval from the Food and Drug Administration. The antibiotic treats community-acquired bacterial pneumonia (CABP), a leading cause of infection-related deaths in the United States.
Based in King of Prussia, Nabriva claims about 5 million cases of pneumonia are reported in the United States each year, and pneumonia is the fifth-leading cause of hospitalizations, writes John George in the Philadelphia Business Journal.
[uam_ad id=”54865″]
Nabriva (NASDAQ: NRBV), led by CEO Ted Schroeder, is based in Ireland and has its U.S. headquarters in King of Prussia.
Nabriva said Xenleta is part of a new class of antibiotics called pleuromutilins that works differently from older antibiotics. Its antibiotic, the company explained, is a semi-synthetic compound designed to inhibit the synthesis of bacterial protein, which is required for bacteria to grow.
The last time the FDA approved a new class of antibiotics for CABP was 2000.
To read the complete story click here.
[uam_ad id=”54875″]
Stay Connected, Stay Informed
Subscribe for great stories in your community!
"*" indicates required fields